Darbepoetin alfa biosimilar - 3SBio
Alternative Names: NuPIAO; Recombinant erythropoiesis stimulating protein - 3SBio; Recombinant erythropoietin stimulating protein - 3SBio; Recombinant erythropoietin stimulating protein - Shenyang Sunshine; rESP - 3SBio; SSS-06Latest Information Update: 09 Feb 2026
At a glance
- Originator 3SBio
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Anaemia
Most Recent Events
- 09 Feb 2026 No development reported - Phase-II for Anaemia in China (SC)(3Sbio pipeline, February 2026)
- 09 Feb 2026 Shenyang Sunshine Pharmaceutical initiates a phase II/III trial for Ananemia (Parenteral, Injection), prior to February 2026 (CTR20250435)
- 15 Jan 2026 NMPA accepts NDA for Darbepoetin alfa biosimilar for Anaemia for review